Population Pharmacokinetic Estimates Suggest Elevated Clearance and Distribution Volume of Desethylamodiaquine in Pediatric Patients with Sickle Cell Disease Treated with Artesunate-Amodiaquine

• Egile Nagusiak: George O. Adjei, MD, PhD (Egilea), Seth K. Amponsah, PhD (Egilea), Bamenla Q. Goka, MB. ChB, MRCP, FWACP (Egilea), Christabel Enweronu-Laryea, MBBS, MSc, FRCPCH (Egilea), Lorna Renner, MB. ChB, MPH, FRCPCH, FGCPS (Egilea), Abdul Malik Sulley, MSc (Egilea), Michael Alifrangis, MSc, PhD (Egilea), Jorgen A.L. Kurtzhals, MD, PhD (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2019-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: There is limited information on the safety or efficacy of currently recommended antimalarial drugs in patients with sickle cell disease (SCD), a population predisposed to worse outcomes if affected by acute malaria. Artesunate-amodiaquine (ASAQ) is the first-line treatment for uncomplica...